Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies

scientific article published on 20 March 2017

Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S1474-4422(17)30056-X
P932PMC publication ID5477770
P698PubMed publication ID28336296

P50authorJon StoesslQ20006927
Kazuko HasegawaQ64858707
Vesna SossiQ67175776
M SchulzerQ67209622
E MakQ67210951
Daryl J WileQ67212681
Audrey J StrongoskyQ114336738
Katherine DinelleQ117251250
Nasim VafaiQ117251251
Jessamyn McKenzieQ117251252
Nicole NeilsonQ117251253
Cyrus P ZabetianQ30362040
Pankaj A AgarwalQ42838307
Elham ShahinfardQ57066883
Ryan J UittiQ64754354
Zbigniew K WszolekQ64754704
P2093author name stringJing Zhang
Mark Guttman
Yu-Shin Ding
Jan Aasly
Mike Adam
P2860cites work???Q64786077
Staging of brain pathology related to sporadic Parkinson's diseaseQ28131702
Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. GeneralizationsQ28236042
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic miceQ29620597
Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET studyQ33668068
Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's diseaseQ34267681
Brain serotonin transporter binding in non-depressed patients with Parkinson's diseaseQ34619565
Spared caudal brainstem SERT binding in early Parkinson's diseaseQ34724279
Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB.Q34801837
Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriersQ35119612
Olfactory dysfunction in LRRK2 G2019S mutation carriersQ35119617
Distribution volume ratios without blood sampling from graphical analysis of PET dataQ36817029
Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomesQ37243261
Prediagnostic presentations of Parkinson's disease in primary care: a case-control studyQ39092409
Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriersQ39477657
Dopamine turnover increases in asymptomatic LRRK2 mutations carriersQ42861721
Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction.Q42872557
Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET studyQ42994792
Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography studyQ43290056
Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's diseaseQ45271401
Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's diseaseQ45346135
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensationQ46635617
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's diseaseQ46935041
DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease.Q47907932
Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporterQ48121057
Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET studyQ48123682
Serotonergic mediated body mass index changes in Parkinson's disease.Q53222060
Olfactory heterogeneity in LRRK2 related Parkinsonism.Q54651567
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectparkinsonian syndromeQ1531991
P304page(s)351-359
P577publication date2017-03-20
P1433published inLancet NeurologyQ15755067
P1476titleSerotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies
P478volume16

Reverse relations

cites work (P2860)
Q64866418Q64866418
Q58598324A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein
Q58730704Altered dopamine release and monoamine transporters in Vps35 p.D620N knock-in mice
Q89776335Clinical and Dopamine Transporter Imaging Characteristics of Leucine- Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study
Q95840882Clinical and Imaging Markers of Prodromal Parkinson's Disease
Q91069104Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study
Q48172009Cognitive and behavioral disorders in Parkinson's disease: an update. I: cognitive impairments
Q53692679Disease progression in LRRK2 parkinsonism.
Q57158118Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder
Q42268862Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice
Q55287139Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET.
Q89521076Is serotonin pathology a good biomarker in vivo for early Parkinson's disease?
Q40964593Neurochemical Systems of the Retina Involved in the Control of Movement.
Q92959125Serotonergic pathology and Braak's staging hypothesis in Parkinson's disease
Q92959120Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study
Q64759313Structural Imaging in Parkinson's Disease: New Developments
Q49886566The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.

Search more.